Advanced search
Publication Cover
OncoImmunology Volume 10, 2021 - Issue 1
Submit an article Journal homepage
5,194
Views
15
CrossRef citations to date
0
Altmetric
Research Article

Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targeting

Christian M. Seitza Department of General Pediatrics, Hematology and Oncology, University Children’s Hospital Tuebingen, GermanyORCID Iconhttps://orcid.org/0000-0002-0520-7866View further author information
ORCID Icon,
Joerg Mittelstaetb R&D Department, Miltenyi Biotec GmbH, Bergisch Gladbach, GermanyView further author information
,
Daniel Atara Department of General Pediatrics, Hematology and Oncology, University Children’s Hospital Tuebingen, GermanyView further author information
,
Jana Haua Department of General Pediatrics, Hematology and Oncology, University Children’s Hospital Tuebingen, GermanyView further author information
,
Selina Reitera Department of General Pediatrics, Hematology and Oncology, University Children’s Hospital Tuebingen, GermanyView further author information
,
Clara Illia Department of General Pediatrics, Hematology and Oncology, University Children’s Hospital Tuebingen, GermanyView further author information
,
Verena Kieblea Department of General Pediatrics, Hematology and Oncology, University Children’s Hospital Tuebingen, GermanyView further author information
,
Fabian Engertb R&D Department, Miltenyi Biotec GmbH, Bergisch Gladbach, GermanyView further author information
,
Britta Dreesb R&D Department, Miltenyi Biotec GmbH, Bergisch Gladbach, GermanyView further author information
,
Giulia Bendera Department of General Pediatrics, Hematology and Oncology, University Children’s Hospital Tuebingen, GermanyView further author information
,
Ann-Christin Krahla Department of General Pediatrics, Hematology and Oncology, University Children’s Hospital Tuebingen, GermanyView further author information
,
Philipp Knopfc Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tuebingen, GermanyView further author information
,
Sarah Schroedera Department of General Pediatrics, Hematology and Oncology, University Children’s Hospital Tuebingen, GermanyView further author information
,
Nikolas Paulsena Department of General Pediatrics, Hematology and Oncology, University Children’s Hospital Tuebingen, GermanyView further author information
,
Alexander Rokhvarguera Department of General Pediatrics, Hematology and Oncology, University Children’s Hospital Tuebingen, GermanyView further author information
,
Sophia Scheuermanna Department of General Pediatrics, Hematology and Oncology, University Children’s Hospital Tuebingen, GermanyView further author information
,
Elena Rappa Department of General Pediatrics, Hematology and Oncology, University Children’s Hospital Tuebingen, GermanyView further author information
,
Anna-Sophia Masta Department of General Pediatrics, Hematology and Oncology, University Children’s Hospital Tuebingen, GermanyView further author information
,
Armin Rabsteyna Department of General Pediatrics, Hematology and Oncology, University Children’s Hospital Tuebingen, Germany;d Cluster of Excellence iFIT (Exc 2180) “Image-guided and Functionally Instructed Tumor Therapies”, University of Tuebingen, GermanyView further author information
,
Sabine Schleichera Department of General Pediatrics, Hematology and Oncology, University Children’s Hospital Tuebingen, GermanyView further author information
,
Stefan Grotea Department of General Pediatrics, Hematology and Oncology, University Children’s Hospital Tuebingen, GermanyView further author information
,
Karin Schilbacha Department of General Pediatrics, Hematology and Oncology, University Children’s Hospital Tuebingen, GermanyView further author information
,
Manfred Kneillingc Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tuebingen, Germany;d Cluster of Excellence iFIT (Exc 2180) “Image-guided and Functionally Instructed Tumor Therapies”, University of Tuebingen, GermanyView further author information
,
Bernd Pichlerc Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tuebingen, Germany;d Cluster of Excellence iFIT (Exc 2180) “Image-guided and Functionally Instructed Tumor Therapies”, University of Tuebingen, GermanyView further author information
,
Dominik Lockb R&D Department, Miltenyi Biotec GmbH, Bergisch Gladbach, GermanyView further author information
,
Bettina Kotterb R&D Department, Miltenyi Biotec GmbH, Bergisch Gladbach, GermanyView further author information
,
Sandra Dapab R&D Department, Miltenyi Biotec GmbH, Bergisch Gladbach, GermanyView further author information
,
Stefan Miltenyib R&D Department, Miltenyi Biotec GmbH, Bergisch Gladbach, GermanyView further author information
,
Andrew Kaiserb R&D Department, Miltenyi Biotec GmbH, Bergisch Gladbach, GermanyView further author information
,
Peter Langa Department of General Pediatrics, Hematology and Oncology, University Children’s Hospital Tuebingen, Germany;d Cluster of Excellence iFIT (Exc 2180) “Image-guided and Functionally Instructed Tumor Therapies”, University of Tuebingen, GermanyView further author information
,
Rupert Handgretingera Department of General Pediatrics, Hematology and Oncology, University Children’s Hospital Tuebingen, Germany;d Cluster of Excellence iFIT (Exc 2180) “Image-guided and Functionally Instructed Tumor Therapies”, University of Tuebingen, GermanyView further author information
&
Patrick Schlegela Department of General Pediatrics, Hematology and Oncology, University Children’s Hospital Tuebingen, Germany;d Cluster of Excellence iFIT (Exc 2180) “Image-guided and Functionally Instructed Tumor Therapies”, University of Tuebingen, Germany;e School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Sydney, Australia;f Cellular Cancer Therapeutics Unit, Children’s Medical Research Institute, Westmead, Australia;g Department of Pediatric Hematology and Oncology, Westmead Children’s Hospital, Westmead, AustraliaCorrespondence[email protected]
View further author information
 show all
Article: 2003532 | Received 22 Jun 2021, Accepted 03 Nov 2021, Published online: 02 Dec 2021

References

  • Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. The New England Journal of Medicine. 2017;377(26):2531–16. doi:10.1056/NEJMoa1707447.
  • Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–1517. doi:10.1056/NEJMoa1407222.
  • Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. The New England Journal of Medicine. 2018;378(5):439–448. doi:10.1056/NEJMoa1709866.
  • Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188–195. doi:10.1182/blood-2014-05-552729.
  • Mackall CL, Miklos DB. CNS Endothelial Cell Activation Emerges as a Driver of CAR T Cell-Associated Neurotoxicity. Cancer Discov. 2017;7(12):1371–1373. doi:10.1158/2159-8290.CD-17-1084.
  • Gauthier J, Turtle CJ. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. Curr Res Transl Med. 2018;66(2):50–52. doi:10.1016/j.retram.2018.03.003.
  • Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, et al. Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discov. 2015;5(12):1282–1295. doi:10.1158/2159-8290.CD-15-1020.
  • Gardner R, Wu D, Cherian S, Fang M, Hanafi LA, Finney O, et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood. 2016;127(20):2406–2410. doi:10.1182/blood-2015-08-665547.
  • Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24(1):20–28. doi:10.1038/nm.4441.
  • Shalabi H, Kraft IL, Wang HW, Yuan CM, Yates B, Delbrook C, Zimbelman JD, Giller R, Stetler-Stevenson M, Jaffe ES, et al. Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma. Haematologica. 2018;103(5):e215–e218. doi:10.3324/haematol.2017.183459.
  • O’Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017;9.
  • Wu CY, Roybal KT, Puchner EM, Onuffer J, Lim WA. Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science. 2015;350(6258):aab4077. doi:10.1126/science.aab4077.
  • Sakemura R, Terakura S, Watanabe K, Julamanee J, Takagi E, Miyao K, Koyama D, Goto T, Hanajiri R, Nishida T, et al. A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration. Cancer Immunol Res. 2016;4(8):658–668. doi:10.1158/2326-6066.CIR-16-0043.
  • Cleemenceau B, Congy-Jolivet N, Gallot G, Vivien R, Gaschet J, Thibault G, Viee H. Antibody-dependent cellular cytotoxicity (ADCC) is mediated by genetically modified antigen-specific human T lymphocytes. Blood. 2006;107(12):4669–4677. doi:10.1182/blood-2005-09-3775.
  • Kudo K, Imai C, Lorenzini P, Kamiya T, Kono K, Davidoff AM, et al. T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing. Cancer Res. 2014;74(1):93–103. doi:10.1158/0008-5472.CAN-13-1365.
  • Tamada K, Geng D, Sakoda Y, Bansal N, Srivastava R, Li Z, et al. Redirecting gene-modified T cells toward various cancer types using tagged antibodies. Clin Cancer Res. 2012;18(23):6436–6445. doi:10.1158/1078-0432.CCR-12-1449.
  • Urbanska K, Lanitis E, Poussin M, Lynn RC, Gavin BP, Kelderman S, et al. A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. Cancer Res. 2012;72(7):1844–1852. doi:10.1158/0008-5472.CAN-11-3890.
  • Lohmueller JJ, Ham JD, Kvorjak M, Finn OJ. mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting. Oncoimmunology. 2017;7:e1368604.
  • Kim MS, Ma JS, Yun H, Cao Y, Kim JY, Chi V, et al. Redirection of genetically engineered CAR-T cells using bifunctional small molecules. J Am Chem Soc. 2015;137(8):2832–2835. doi:10.1021/jacs.5b00106.
  • Ma JS, Kim JY, Kazane SA, Choi SH, Yun HY, Kim MS, et al. Versatile strategy for controlling the specificity and activity of engineered T cells. Proc Natl Acad Sci U S A. 2016;113(4):E450–458. doi:10.1073/pnas.1524193113.
  • Rodgers DT, Mazagova M, Hampton EN, Cao Y, Ramadoss NS, Hardy IR, et al. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Proc Natl Acad Sci U S A. 2016;113(4):E459–468. doi:10.1073/pnas.1524155113.
  • Cartellieri M, Feldmann A, Koristka S, Arndt C, Loff S, Ehninger A, et al. Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts. Blood Cancer J. 2016;6(8):e458. doi:10.1038/bcj.2016.61.
  • Cho JH, Collins JJ, Wong WW. Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses. Cell. 2018;173(6):1426–1438.e11. doi:10.1016/j.cell.2018.03.038.
  • Seidel UJ, Schlegel P, Grosse-Hovest L, Hofmann M, Aulwurm S, Pyz E, et al. Reduction of minimal residual disease in pediatric B-lineage acute Lymphoblastic Leukemia by an Fc-optimized CD19 Antibody. Mol Ther. 2016;24(9):1634–1643. doi:10.1038/mt.2016.141.
  • Handgretinger R, Anderson K, Lang P, Dopfer R, Klingebiel T, Schrappe M, Reuland P, Gillies SD, Reisfeld RA, Niethammer D, et al. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. European Journal of Cancer. 1995;31A(2):261–267. doi:10.1016/0959-8049(94)00413-Y.
  • Hudecek M, Sommermeyer D, Kosasih PL, Silva-Benedict A, Liu L, Rader C, et al. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res. 2015;3(2):125–135. doi:10.1158/2326-6066.CIR-14-0127.
  • Zah E, Lin MY, Silva-Benedict A, Jensen MC, Chen YY. T cells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells. Cancer Immunol Res. 2016;4(6):498–508. doi:10.1158/2326-6066.CIR-15-0231.
  • Viaud S, Ma JSY, Hardy IR, Hampton EN, Benish B, Sherwood L, et al. Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory. Proc Natl Acad Sci U S A. 2018;115(46):E10898–E10906. doi:10.1073/pnas.1810060115.
  • Lock D, Mockel-Tenbrinck N, Drechsel K, Barth C, Mauer D, Schaser T, et al. Automated manufacturing of potent CD20-directed chimeric antigen receptor T cells for clinical use. Hum Gene Ther. 2017;28:914–925.
  • Zhu F, Shah N, Xu H, Schneider D, Orentas R, Dropulic B, et al. Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center. Cytotherapy. 2018;20(3):394–406. doi:10.1016/j.jcyt.2017.09.005.
  • Park JH, Riviere I, Gonen M, Wang X, Senechal B, Curran KJ, et al. Long-Term follow-up of CD19 CAR therapy in acute lymphoblastic Leukemia. The New England Journal of Medicine. 2018;378(5):449–459. doi:10.1056/NEJMoa1709919.
  • Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33:540–549.
  • Maldini CR, Ellis GI, Riley JL. CAR T cells for infection, autoimmunity and allotransplantation. Nature Reviews Immunology. 2018;18(10):605–616. doi:10.1038/s41577-018-0042-2.
  • Nelson AL. Antibody fragments: hope and hype. MAbs. 2010;2(1):77–83. doi:10.4161/mabs.2.1.10786.
  • Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer. 2001;1(2):118–129. doi:10.1038/35101072.
  • van Dam H, Castellazzi M. Distinct roles of Jun: Fos and Jun: ATF dimers in oncogenesis. Oncogene. 2001;20(19):2453–2464. doi:10.1038/sj.onc.1204239.
  • Jain A, Barve A, Zhao Z, Jin W, Cheng K. Comparison of avidin, neutravidin, and streptavidin as nanocarriers for efficient siRNA delivery. Mol Pharm. 2017;14(5):1517–1527. doi:10.1021/acs.molpharmaceut.6b00933.
  • Martorell A, Alonso E, Bone J, Echeverria L, Lopez MC, Martin F, et al. Position document: igE-mediated allergy to egg protein. Allergol Immunopathol (Madr). 2013;41(5):320–336. doi:10.1016/j.aller.2013.03.005.
  • Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy. Cancer Discovery. 2018;8(10):1219–1226. doi:10.1158/2159-8290.CD-18-0442.
  • Kloss CC, Condomines M, Cartellieri M, Bachmann M, Sadelain M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol. 2013;31:71–75.
  • Lanitis E, Poussin M, Klattenhoff AW, Song D, Sandaltzopoulos R, June CH, et al. Chimeric antigen receptor t cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Cancer Immunol Res. 2013;1(1):43–53. doi:10.1158/2326-6066.CIR-13-0008.
  • Roybal KT, Rupp LJ, Morsut L, Walker WJ, McNally KA, Park JS, et al. Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits. Cell. 2016;164(4):770–779. doi:10.1016/j.cell.2016.01.011.
  • Srivastava S, Salter AI, Liggitt D, Yechan-Gunja S, Sarvothama M, Cooper K, et al. Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting. Cancer Cell. 2019;35(489–503):e488. doi:10.1016/j.ccell.2019.02.003.
  • Fedorov VD, Themeli M, Sadelain M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med. 2013;5(215):215ra172. doi:10.1126/scitranslmed.3006597.
  • Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, et al. A third-generation lentivirus vector with a conditional packaging system. J Virol. 1998;72(11):8463–8471. doi:10.1128/JVI.72.11.8463-8471.1998.
  • Vick B, Rothenberg M, Sandhofer N, Carlet M, Finkenzeller C, Krupka C, et al. An advanced preclinical mouse model for acute myeloid leukemia using patients’ cells of various genetic subgroups and in vivo bioluminescence imaging. PLoS One. 2015;10(3):e0120925. doi:10.1371/journal.pone.0120925.
  • Wing A, Fajardo CA, Posey AD Jr., Shaw C, Da T, Young RM, et al. Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager. Cancer Immunol Res. 2018;6(5):605–616. doi:10.1158/2326-6066.CIR-17-0314.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.